Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

December 17, 2021

Top 5 Lung Cancer-Related Stories of 2021

Author(s):

Brielle Benyon

CURE® took a look back at our most-read lung cancer stories from this year.

From Food and Drug Administration (FDA) approvals to new research developments and personal stories of hope and resilience, so much has happened in the lung cancer space in the year 2021.

CURE® took a look back at the most-read lung cancer-related articles of the year and compiled them for our readers. They were:

1. A Non-Small Cell Lung Cancer Survivor Shares Her Story

As an endurance athlete and healthy mother of two, Tabitha Paccione was shocked in 2016 when she received a diagnosis of stage 4 lung cancer at the age of 35. In this article from CURE®’s Winter 2021 issue, Paccione discusses the treatments that are keeping her alive and the hope that keeps her going. “The only reason I share my story is because I want to give that next lung cancer survivor the help that they need to push forward and to live their lives,” she said.

2. Could T-Cell Therapy Be the Next Advancement in Lung Cancer Immunotherapy?

Immunotherapy has drastically changed the lung cancer treatment landscape in recent years, and in this article, CURE®’s editor-in-chief Dr. Debu Tripathy theorizes on where to go from here. CAR-T cell therapy, which continues to be used in the blood cancer space, is in the early stages of development for non-small cell lung cancer.

3. An Inspiring, Guiding Light Through Lung Cancer

Every year, CURE® honors individuals who are making an impact on the lung cancer community through our Lung Cancer Heroes® program. In this essay, patient Leah “Cherry” Lommen writes of her physician, Dr. Aaron Mansfield of the Mayo Clinic, stating that he “strengthens you with the scientific knowledge he provides, with his courage as a role model and with his fighting spirit.” Lommen died shortly after submitting the essay, but her kind words for her favorite doctor will live on.

4. FDA Approves Drug to Reduce Bone Marrow Suppression Caused by Chemotherapy in Certain Patients With Lung Cancer

This February, the Food and Drug Administration approved Cosela (trilaciclib) for the treatment of bone marrow suppression in adults undergoing chemotherapy to treat extensive-stage small-cell lung cancer that has spread beyond the lungs. By protecting the bone marrow function, the approval of Cosela is likely to help patients complete their cancer treatment on time and according to plan, Dr. Albert Deisseroth said.

5. Early Introduction to Supportive Care Greatly Benefits Older Patients With Lung Cancer

Cancer treatment can be rough, especially for older individuals who may have more comorbidities. This article explores the benefit of supportive care, which can include the treatment of side effects, social work, nutrition, physical therapy, speech therapy, home care, palliative care and the management of other health conditions. “We have more options to help patients and more supportive measures in place than we did even just a few years ago. It has been very beneficial to our patients,” said Dr. Christine Ciunci.

Visit CURE®’s lung cancer page for complete coverage on the disease.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Image of man.
Image of doctor.
Image of Dr. Boffa.
Most patients in accredited hospitals had smoking discussions documented, showing key care opportunities and smoking’s impact on treatment outcomes.
Image of Dr. Reznick
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
Related Content
Advertisement
The U.S. FDA has approved treatment with Ibtrozi patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
June 11th 2025

FDA Approves Ibtrozi for ROS1+ Advanced Non-Small Cell Lung Cancer

Spencer Feldman
The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lungs.
June 10th 2025

The LAURA Trial May Lead to a New Era of Care in Lung Cancer

Ryan Scott
Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
image of lungs
June 8th 2025

Targeted Chemo Improves Survival in Early-Stage Lung Cancer

Jordyn Sava
Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.
Image of lung.
June 6th 2025

MVdeltaC Earns Orphan Drug Status for Pleural Mesothelioma

Spencer Feldman
The FDA granted orphan drug designation to MVdeltaC, a measles virus-based immunotherapy, for pleural mesothelioma, supporting its future development.
Related Content
Advertisement
The U.S. FDA has approved treatment with Ibtrozi patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
June 11th 2025

FDA Approves Ibtrozi for ROS1+ Advanced Non-Small Cell Lung Cancer

Spencer Feldman
The U.S. FDA has approved treatment with Ibtrozi for patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lungs.
June 10th 2025

The LAURA Trial May Lead to a New Era of Care in Lung Cancer

Ryan Scott
Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell lung cancer.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
image of lungs
June 8th 2025

Targeted Chemo Improves Survival in Early-Stage Lung Cancer

Jordyn Sava
Using a 14-gene test to guide chemotherapy significantly improved disease-free survival in patients with early nonsquamous lung cancer.
Image of lung.
June 6th 2025

MVdeltaC Earns Orphan Drug Status for Pleural Mesothelioma

Spencer Feldman
The FDA granted orphan drug designation to MVdeltaC, a measles virus-based immunotherapy, for pleural mesothelioma, supporting its future development.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.